Onconetix, Inc.

Nasdaq:ONCO

Pharmaceutical Preparations·CINCINNATI, OH

CEO

Schiess Ralph

Summary Financials

Revenue

$58,465

+0.0% YoY

FY 2024

Adj. EBITDA

-$36.0M

-61622.9% margin

FY 2024

Net Income

-$37.4M

-63986.5% margin

FY 2024

EPS (Diluted)

-$87.45

FY 2024

Stock Price

$0.49

-13.4%

2026-03-09

52W Range

$0.47 – $18.80

P/E Ratio

-0.0x

Market Cap

$767,536.522

Cash

$1.9M

FY 2022

Total Debt

$9.7M

FY 2024

Net Debt

$7.8M

FY 2024

Enterprise Value

$8.6M

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

-0.2x

Employees

—

Revenue

$58,465

+0.0% YoY

FY 2024

Adj. EBITDA

-$36.0M

-61622.9% margin

FY 2024

Net Income

-$37.4M

-63986.5% margin

FY 2024

EPS (Diluted)

-$87.45

FY 2024

Stock Price

$0.49

-13.4%

2026-03-09

52W Range

$0.47 – $18.80

P/E Ratio

-0.0x

Market Cap

$767,536.522

Cash

$1.9M

FY 2022

Total Debt

$9.7M

FY 2024

Net Debt

$7.8M

FY 2024

Enterprise Value

$8.6M

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

-0.2x

Employees

—